Moleculin Biotech (MBRX) News Today $2.67 0.00 (0.00%) (As of 12:47 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Moleculin Biotech Announces Positive Findings on Annamycin for AML Patients, Overcoming Venetoclax ResistanceNovember 20 at 2:11 AM | americanbankingnews.comMoleculin Biotech Advances Annamycin for AML TreatmentNovember 18 at 5:21 PM | markets.businessinsider.comMoleculin Biotech announces new findings on AnnamycinNovember 18 at 5:21 PM | markets.businessinsider.comNew Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AMLNovember 18 at 8:15 AM | prnewswire.comWhat is Roth Capital's Forecast for MBRX Q1 Earnings?November 18 at 3:27 AM | americanbankingnews.comMoleculin Biotech Amends Clinical Trial Protocol for Phase 3 TrialNovember 17, 2024 | americanbankingnews.comMoleculin Biotech Unveils New Corporate PresentationNovember 14, 2024 | tipranks.comMoleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025November 14, 2024 | prnewswire.comMoleculin Biotech Announces Financial Results for Quarter Ending September 30, 2024November 14, 2024 | americanbankingnews.comStockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX)November 13, 2024 | americanbankingnews.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | msn.comMoleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)November 12, 2024 | prnewswire.comMoleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | seekingalpha.comMoleculin Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 11, 2024 | prnewswire.comInsights Ahead: Moleculin Biotech's Quarterly EarningsNovember 7, 2024 | benzinga.comMoleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and WebcastNovember 5, 2024 | prnewswire.comMoleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of AnnamycinNovember 4, 2024 | prnewswire.comMoleculin Biotech’s Annual Meeting Decisions and ElectionsOctober 26, 2024 | markets.businessinsider.comMoleculin Biotech Highlights Annamycin’s AML Treatment PotentialOctober 18, 2024 | finance.yahoo.comTranscript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now AvailableOctober 17, 2024 | prnewswire.comMoleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ...October 11, 2024 | uk.finance.yahoo.comMoleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024October 7, 2024 | prnewswire.comMoleculin to Present at Two Upcoming Investor ConferencesOctober 4, 2024 | prnewswire.comMoleculin Biotech IncSeptember 25, 2024 | money.usnews.comMoleculin Biotech Sees Positive Data From Annamycin StudySeptember 24, 2024 | marketwatch.comMoleculin Biotech Shares Rise 12% After Positive Annamycin DataSeptember 24, 2024 | marketwatch.comMoleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of SarcomaSeptember 23, 2024 | prnewswire.comMoleculin Participates in Virtual Investor "What this Means" SegmentSeptember 16, 2024 | prnewswire.comMoleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of GlioblastomaSeptember 9, 2024 | prnewswire.comMoleculin to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | prnewswire.comMoleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment WebinarAugust 26, 2024 | prnewswire.comMoleculin Announces Closing of up to $16.5 Million Public OfferingAugust 19, 2024 | prnewswire.comMoleculin sets terms for $5.5 million public offeringAugust 18, 2024 | uk.investing.comMoleculin Biotech gets Buy rating from Roth with strong trial resultsAugust 16, 2024 | investing.comMoleculin Announces Pricing of up to $16.5 Million Public OfferingAugust 16, 2024 | finance.yahoo.comMoleculin Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 14, 2024 | prnewswire.comMoleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ETAugust 5, 2024 | prnewswire.comBuy Rating for Moleculin Biotech on Promising Annamycin Trials and Undervalued SharesAugust 2, 2024 | markets.businessinsider.comMoleculin Announces Plans for MIRACLE Phase 3 Pivotal TrialAugust 1, 2024 | prnewswire.comMoleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AMLJuly 10, 2024 | prnewswire.comMoleculin Announces Additional Positive Preliminary Interim Data from AML Clinical TrialJune 14, 2024 | prnewswire.comMoleculin to Present at the Virtual Investor Pitch ConferenceJune 12, 2024 | prnewswire.comMoleculin to Participate in the Virtual Investor Lunch Break SeriesJune 5, 2024 | prnewswire.comMoleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid CongressMay 16, 2024 | prnewswire.comMoleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)May 15, 2024 | prnewswire.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2024 Earnings Call TranscriptMay 14, 2024 | msn.comMoleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...May 14, 2024 | finance.yahoo.comMoleculin Biotech, Inc.: Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | finanznachrichten.deMoleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | prnewswire.comMBRX Stock Earnings: Moleculin Biotech Beats EPS for Q1 2024May 10, 2024 | investorplace.com Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. MBRX Media Mentions By Week MBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MBRX News Sentiment▼0.570.47▲Average Medical News Sentiment MBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MBRX Articles This Week▼91▲MBRX Articles Average Week Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ACST News Today CTXR News Today PMN News Today LTRN News Today LIAN News Today BIVI News Today RNXT News Today SRZN News Today KALA News Today DARE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MBRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MBRX Stock Alerts